Study #2022-0901
A pivotal study to evaluate the safety and effectiveness of Exablate Model 4000 using microbubble resonators to temporarily mediate blood-brain barrier disruption (BBBD) for liquid biopsy in subjects with glioblastoma brain tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma;Glioma;Liquid Biopsy
Study phase:
Not applicable
Physician name:
Jeffrey Weinberg
Department:
Neurosurgery
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.